PL3068421T3 - Selektywne związki pyy i ich zastosowania - Google Patents

Selektywne związki pyy i ich zastosowania

Info

Publication number
PL3068421T3
PL3068421T3 PL14798834T PL14798834T PL3068421T3 PL 3068421 T3 PL3068421 T3 PL 3068421T3 PL 14798834 T PL14798834 T PL 14798834T PL 14798834 T PL14798834 T PL 14798834T PL 3068421 T3 PL3068421 T3 PL 3068421T3
Authority
PL
Poland
Prior art keywords
pyy compounds
selective
selective pyy
compounds
pyy
Prior art date
Application number
PL14798834T
Other languages
English (en)
Inventor
Søren Østergaard
Kilian Waldemar Conde Frieboes
Birgit Wieczorek
Jens Kaalby Thomsen
Birgitte Schjellerup Wulff
Carsten Jessen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL3068421T3 publication Critical patent/PL3068421T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
PL14798834T 2013-11-15 2014-11-13 Selektywne związki pyy i ich zastosowania PL3068421T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13193082 2013-11-15
US201361906020P 2013-11-19 2013-11-19
EP14176725 2014-07-11
EP14798834.9A EP3068421B1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof
PCT/EP2014/074476 WO2015071355A1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof

Publications (1)

Publication Number Publication Date
PL3068421T3 true PL3068421T3 (pl) 2019-11-29

Family

ID=53056816

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14798834T PL3068421T3 (pl) 2013-11-15 2014-11-13 Selektywne związki pyy i ich zastosowania

Country Status (15)

Country Link
US (2) US10246497B2 (pl)
EP (1) EP3068421B1 (pl)
JP (1) JP6602760B2 (pl)
KR (1) KR20160075819A (pl)
CN (1) CN105722526B (pl)
AU (1) AU2014350197B2 (pl)
BR (1) BR112016010383A2 (pl)
CA (1) CA2929672A1 (pl)
IL (1) IL245045B (pl)
MX (1) MX369818B (pl)
PL (1) PL3068421T3 (pl)
RS (1) RS59026B1 (pl)
SI (1) SI3068421T1 (pl)
TW (1) TWI661835B (pl)
WO (1) WO2015071355A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6629198B2 (ja) * 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
CA2988500A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
US12569543B2 (en) * 2016-04-28 2026-03-10 Novo Nordisk A/S Semaglutide in cardiovascular conditions
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
JP2020527159A (ja) 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス Ｅｇｆ（ａ）類似体、その製造、製剤および使用
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
EP3717508A1 (en) 2017-12-01 2020-10-07 The University of Copenhagen Peptide hormone with one or more o-glycans
KR20200131812A (ko) * 2018-01-09 2020-11-24 길라 테라퓨틱스, 인코포레이티드 대사 질병을 치료하기 위한 조성물 및 방법
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
GB2573145A (en) 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CN114206375A (zh) * 2019-08-07 2022-03-18 诺和诺德股份有限公司 包含pyy化合物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
MX2022005661A (es) * 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
KR20230106616A (ko) * 2020-11-09 2023-07-13 엠바크 바이오테크 에이피에스 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue
WO2025128624A2 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
MY133223A (en) 1998-06-08 2007-10-31 Schering Corp Neuropeptide y5 receptor antagonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU2002230843B8 (en) 2000-12-14 2007-05-17 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CA2550050A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
AU2005224027B2 (en) 2004-03-17 2011-05-26 7Tm Pharma A/S Y2/Y4 selective receptor agonists for therapeutic interventions
CN100425282C (zh) 2004-03-17 2008-10-15 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
PL2060266T3 (pl) 2004-03-17 2012-01-31 7Tm Pharma As Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
KR20080033392A (ko) 2005-07-11 2008-04-16 나스텍 파마수티컬 컴퍼니 인코포레이티드 펩타이드 ｙｙ의 향상된 점막 전달을 위한 제형들
CA2616583A1 (en) 2005-07-18 2007-01-25 Novo-Nordisk A/S Peptides for use in the treatment of obesity
EA200800875A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
EA200800874A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
CN101970475A (zh) 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
AU2008297885A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of GLP-1 as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
WO2009138511A1 (en) 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
CN102202681A (zh) 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
US10246497B2 (en) * 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
CA2988500A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
IL245045B (en) 2019-09-26
CN105722526A (zh) 2016-06-29
CA2929672A1 (en) 2015-05-21
AU2014350197A1 (en) 2016-05-05
EP3068421A1 (en) 2016-09-21
US20150152150A1 (en) 2015-06-04
IL245045A0 (en) 2016-05-31
CN105722526B (zh) 2020-12-08
US20160289283A1 (en) 2016-10-06
TW201605467A (zh) 2016-02-16
US10246497B2 (en) 2019-04-02
JP2017505284A (ja) 2017-02-16
EP3068421B1 (en) 2019-04-17
BR112016010383A2 (pt) 2017-12-05
JP6602760B2 (ja) 2019-11-06
MX2016006053A (es) 2016-08-17
RS59026B1 (sr) 2019-08-30
US9085637B2 (en) 2015-07-21
WO2015071355A1 (en) 2015-05-21
SI3068421T1 (sl) 2019-08-30
TWI661835B (zh) 2019-06-11
MX369818B (es) 2019-11-22
AU2014350197B2 (en) 2018-10-04
KR20160075819A (ko) 2016-06-29

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and their uses
IL276113B (en) Electronic smoking part and electronic smoking device
IL245045A0 (en) Selective pyy compounds and their uses
IL240275B (en) Selective antisense compounds and their uses
ZA201603549B (en) New pesticidal compounds and uses
GB201323008D0 (en) Compounds and uses thereof
GB201317802D0 (en) SmartHaler patent application
GB201300707D0 (en) Compounds and processes
IL244214B (en) Thienopiperidine derivative and its use
GB201307233D0 (en) Compounds and uses thereof
DK3056208T3 (en) Immunpotentiator
ZA201601880B (en) Hetero-transglycosylase and uses thereof
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201301329D0 (en) Fluidfoil
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
HUE043900T2 (hu) Szelektív PYY vegyületek és alkalmazásuk
AU5375P (en) Sungeloho Angelonia angustifolia
AU5374P (en) Sungelodepi Angelonia angustifolia
AU5373P (en) Sungelobu Angelonia angustifolia
GB201309248D0 (en) Compounds and combinations
GB201323005D0 (en) Compounds and uses thereof
GB201320161D0 (en) Compounds and their uses
GB201307202D0 (en) New compounds and uses